AR053651A1 - Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama - Google Patents
Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mamaInfo
- Publication number
- AR053651A1 AR053651A1 ARP050104588A ARP050104588A AR053651A1 AR 053651 A1 AR053651 A1 AR 053651A1 AR P050104588 A ARP050104588 A AR P050104588A AR P050104588 A ARP050104588 A AR P050104588A AR 053651 A1 AR053651 A1 AR 053651A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- breast cancer
- aromatase inhibitor
- ctla4
- antictla4
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 4
- 229940122815 Aromatase inhibitor Drugs 0.000 title abstract 3
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229960000255 exemestane Drugs 0.000 abstract 1
- 102000043321 human CTLA4 Human genes 0.000 abstract 1
- 229960005386 ipilimumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Administracion de un anticuerpo anti-CTLA4, particularmente anticuerpos humanos contra CTLA4 humano, tal como los que tienen secuencias de aminoácidos de los anticuerpos 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1 y 10D1 (MDX-010), en combinacion con un inhibidor de aromatasa, para el tratamiento del cáncer de mama. Más particularmente, se refiere a la administracion de un anticuerpo anti-CTLA4 y exemestano para el tratamiento del cáncer de mama, composicion farmacéutica y el uso de un anticuerpo anti-CTLA4. Reivindicacion 16: Una composicion farmacéutica para el tratamiento del cáncer de mama, que comprende: una cantidad terapéuticamente eficaz de un anticuerpo anti-CTLA4; una cantidad terapéuticamente eficaz de un inhibidor de aromatasa; y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62485604P | 2004-11-04 | 2004-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053651A1 true AR053651A1 (es) | 2007-05-16 |
Family
ID=35825412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104588A AR053651A1 (es) | 2004-11-04 | 2005-11-02 | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1819735A1 (es) |
| JP (1) | JP2008518902A (es) |
| KR (1) | KR20070067702A (es) |
| CN (1) | CN101052655A (es) |
| AR (1) | AR053651A1 (es) |
| AU (1) | AU2005300315A1 (es) |
| BR (1) | BRPI0515735A2 (es) |
| CA (1) | CA2586844A1 (es) |
| IL (1) | IL182244A0 (es) |
| MX (1) | MX2007003804A (es) |
| NO (1) | NO20072576L (es) |
| RU (1) | RU2007114111A (es) |
| TW (1) | TW200621804A (es) |
| WO (1) | WO2006048749A1 (es) |
| ZA (1) | ZA200702577B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2605796A1 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| WO2007008463A2 (en) * | 2005-07-07 | 2007-01-18 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| JP2011509299A (ja) * | 2008-01-08 | 2011-03-24 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| JP5684130B2 (ja) | 2008-09-26 | 2015-03-11 | トカジェン インコーポレーテッド | 組換えベクター |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| CN107056951A (zh) | 2008-10-02 | 2017-08-18 | 阿帕特夫研究和发展有限公司 | Cd86拮抗物多靶点结合蛋白 |
| SMT201700293T1 (it) * | 2009-07-20 | 2017-07-18 | Bristol Myers Squibb Co | Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative |
| CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
| HUE042327T2 (hu) | 2011-08-30 | 2019-06-28 | Astex Pharmaceuticals Inc | Decitabin-származék készítmények |
| ES3023516T3 (en) * | 2011-10-14 | 2025-06-02 | Hoffmann La Roche | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| KR102125658B1 (ko) | 2012-05-04 | 2020-06-22 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
| CN103768596B (zh) * | 2012-10-17 | 2016-06-22 | 苏州丁孚靶点生物技术有限公司 | 用于肿瘤治疗的组合产品、其用途及相关方法 |
| EP3623478A1 (en) | 2012-10-25 | 2020-03-18 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| CN110448566A (zh) | 2013-03-01 | 2019-11-15 | 阿斯泰克斯制药公司 | 药物组合 |
| CN105636986B (zh) * | 2013-10-18 | 2020-05-12 | 瑞泽恩制药公司 | 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物 |
| HK1254645A1 (zh) | 2015-07-02 | 2019-07-26 | Otsuka Pharmaceutical Co., Ltd. | 冻乾药物组合物 |
| WO2017040815A1 (en) | 2015-09-04 | 2017-03-09 | Tocagen Inc. | Recombinant vectors comprising 2a peptide |
| CN106883298B (zh) * | 2015-12-16 | 2021-12-17 | 上海康岱生物医药技术股份有限公司 | 双特异性偶联抗体及其制法和用途 |
| ES3041885T3 (en) | 2016-01-08 | 2025-11-17 | Replimune Ltd | Engineered virus |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| SG11201810509PA (en) | 2016-06-20 | 2018-12-28 | Kymab Ltd | Anti-pd-l1 antibodies |
| JP7198666B2 (ja) * | 2016-08-26 | 2023-01-04 | 哲治 奥野 | 微小血管血流低減剤およびその利用 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN114984206A (zh) | 2017-03-02 | 2022-09-02 | 基因泰克公司 | Her2阳性乳腺癌的辅助治疗 |
| WO2018167780A1 (en) * | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| SG11202000932XA (en) | 2017-08-03 | 2020-02-27 | Otsuka Pharma Co Ltd | Drug compound and purification methods thereof |
| EP4110347A4 (en) * | 2020-02-27 | 2024-05-29 | University of Washington | COMPOSITION AND METHOD FOR PREPARING A LONG-ACTING INJECTABLE SUSPENSION CONTAINING MULTIPLE ANTI-CANCER DRUGS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
-
2005
- 2005-10-24 CA CA002586844A patent/CA2586844A1/en not_active Abandoned
- 2005-10-24 BR BRPI0515735-8A patent/BRPI0515735A2/pt not_active IP Right Cessation
- 2005-10-24 AU AU2005300315A patent/AU2005300315A1/en not_active Abandoned
- 2005-10-24 MX MX2007003804A patent/MX2007003804A/es unknown
- 2005-10-24 WO PCT/IB2005/003307 patent/WO2006048749A1/en not_active Ceased
- 2005-10-24 KR KR1020077010096A patent/KR20070067702A/ko not_active Ceased
- 2005-10-24 EP EP05798369A patent/EP1819735A1/en not_active Ceased
- 2005-10-24 RU RU2007114111/13A patent/RU2007114111A/ru unknown
- 2005-10-24 JP JP2007538539A patent/JP2008518902A/ja not_active Withdrawn
- 2005-10-24 CN CNA2005800377929A patent/CN101052655A/zh active Pending
- 2005-11-01 TW TW094138271A patent/TW200621804A/zh unknown
- 2005-11-02 AR ARP050104588A patent/AR053651A1/es not_active Application Discontinuation
-
2007
- 2007-03-27 IL IL182244A patent/IL182244A0/en unknown
- 2007-03-28 ZA ZA200702577A patent/ZA200702577B/en unknown
- 2007-05-21 NO NO20072576A patent/NO20072576L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007003804A (es) | 2007-04-23 |
| IL182244A0 (en) | 2007-09-20 |
| CN101052655A (zh) | 2007-10-10 |
| CA2586844A1 (en) | 2006-05-11 |
| JP2008518902A (ja) | 2008-06-05 |
| EP1819735A1 (en) | 2007-08-22 |
| RU2007114111A (ru) | 2008-12-10 |
| BRPI0515735A2 (pt) | 2011-10-11 |
| TW200621804A (en) | 2006-07-01 |
| NO20072576L (no) | 2007-08-03 |
| KR20070067702A (ko) | 2007-06-28 |
| WO2006048749A1 (en) | 2006-05-11 |
| ZA200702577B (en) | 2008-07-30 |
| AU2005300315A1 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| AR109461A2 (es) | Formulación de anticuerpo anti-cd20 y su uso para preparar un medicamento | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| MX347525B (es) | Inhibidores de tirosina cinasa de bruton. | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| CY1110013T1 (el) | Συνδυασμοι για θεραπεια πολλαπλου μυελωματος | |
| AR054237A1 (es) | Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| CU23821A3 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| WO2008091620A3 (en) | Combination therapy comprising romidepsin and i.a. bortezomib | |
| MX353964B (es) | Agentes terapeuticos y usos de los mismos. | |
| CL2008001297A1 (es) | N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer. | |
| BRPI0516531A (pt) | imunoterapia de distúrbios auto-imunes | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| DOP2009000208A (es) | Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| CL2008002466A1 (es) | Composicion farmaceutica topica anhidra que comprende un vasodilatador y un vehiculo aceptable; uso de la composicion anhidra topica en las areas genitales para obtener bienestar sexual mejorado. | |
| ECSP066878A (es) | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |